Evidence map›Paper›PMID 42855701›Full record

ArticleJournal of translational medicine2026

Improved allocation strategies for red cell units of blood group O and RhD-negative revealed by current suboptimal utilization.

Abdullah Alswied, Willy Albert Flegel

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Abdullah AlswiedDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, 20892, MD, USA.
Willy Albert FlegelDepartment of Transfusion Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, 20892, MD, USA. bill.flegel@nih.gov.ORCID http://orcid.org/0000-0002-1631-7198

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDemand for O RhD-negative red cells continues to rise, while overall red cell transfusions have decreased, compounding inventory management challenges. We analyzed O RhD-negative red cell utilization in a large publicly available database.

methodsData from 378,855 red cell transfusions were evaluated using the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Utilization patterns, recipient demographics, and their correlation with the age of red cell units at transfusion were examined.

resultsThe majority of O RhD-negative units were transfused to patients with blood groups other than O RhD-negative (54.5%). A larger percentage of O RhD-negative red cells were transfused after 35 days of collection (41%), compared to other blood groups (18.7%). Patients over 50 years, males, non-O RhD-negative and RhD-positive individuals had higher odds of receiving units stored more than 35 days. Patients with higher hemoglobin concentrations were more likely to receive older blood units. DISCUSSION: The analysis identified opportunities to improve the allocation of O RhD-negative red cell units, highlighting current inventory practices as suboptimal. The findings call for refined allocation strategies to improve the utilization of this limited resource. The implementation of real-time management approaches may balance the retention of such red cell units with the needs of patients who benefit from the use of RhD-negative blood.

Indexed as

ABO Blood-Group SystemErythrocytesErythrocyte TransfusionResource AllocationRh-Hr Blood-Group SystemFemaleHumansMaleMiddle AgedABO Blood-Group SystemRh-Hr Blood-Group SystemRho(D) antigenBlood allocationInventory managementTransfusion practicesUniversal donor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.